Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
- Sponsor
- Peking Union Medical College Hospital
- Study ID
- NCT04560127
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Radioactive Iodine-refractory Differentiated Thyroid Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Camrelizumab combination with Apatinib — DRUGApatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
Study Details
This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive Iodine-refractory Differentiated Thyroid Cancer (RAIR-DTC).
Key Dates
- Start date
- Sep 23, 2020
- Status verified
- Jul 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Camrelizumab combination with ApatinibApatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
Primary Outcome Measure
Objective Response Rate (ORR) [ Time Frame: Time Frame: two years ]